Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Kite Pharma Inc., of Los Angeles, said it closed a $20 million private placement of shares of its Series A preferred stock...Receptos will use the proceeds to support clinical work in multiple sclerosis, inflammatory bowel disease and allergic/immune-mediate disorders. (See BioWorld Today

Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months...The scope of the public offering – on the heels of five partnerships generating more than $125 million in up-front payments in the last 16 months – is designed to plug those development gaps

Astellas Pharma Inc., of Tokyo, and Drais Pharmaceuticals Inc., of Bridgewater, N.J., will repeat for the third time a spinout maneuver that has been successful with two other programs in the past...Portola Pharmaceuticals Inc., of South San Francisco, set the price range for its proposed initial public offering (IPO), aiming to sell 6.9 million shares priced between $13 and $16 each

shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection...The firm also has programs in two big pharma partnerships...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.

ERYtech Pharma SA, of Lyon, France, has had its prospectus accepted for a proposed initial public offering on the NYSE Euronext exchange in Paris

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes...Omthera Pharmaceuticals Inc., of Princeton, N.J., priced its initial public offering (IPO) at $8 apiece, below the company's target range of $12 to $14

biotech to file for an initial public offering (IPO) this year, taking advantage of the emerging growth company provision in the Jumpstart Our Business Start-ups Act and aiming to raise as much as $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease (IBD) and allergic/immune-mediate disorders...MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price

A big pharma partner could ease some of the pressure on Vivus...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

priced a $56 million initial public offering (IPO) and received a warm welcome from Wall Street, as its newly listed shares shot up 22.7 percent on its first day of trading...and London-based GW Pharma plc, which is seeking a Nasdaq listing and a capital raise. (See BioWorld Today, March 11, 2013, March 12, 2013, and March 20, 2013.) In other financings news

upsized a public offering of about 2.9 million shares of common stock, priced at $20.75, seeking to raise $59.7 million...priced a public offering, seeking to raise $207.2 million. (See story in this issue.) Since March 1, Achillion Pharmaceuticals Inc., Enanta Pharmaceuticals Inc

The company disclosed its plan to begin a public offering to raise $125 million more, pursuant to a shelf registration last week. (See BioWorld Today, Feb 22, 2013...Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets

Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack expression of the estrogen and progesterone receptors, while also lacking HER2 amplification, i.e., TNBC...Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1.2 million shares at the public offering price of $20.13 per share

Arno is conducting clinical and preclinical studies of three drug candidates to treat a variety of cancers...MEI Pharma Inc., of San Diego, completed a private placement of common stock and warrants in a financing led by new investors Vivo Ventures and New Leaf Venture Partners...NeRRe Therapeutics Ltd., of London, raised £11.5 million (US$18.4 million) to develop a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GlaxoSmithKline plc, also of London. #kicker123

The public offering was priced at Wednesday's closing price, a discount of less than 5 percent from the stock's high mark two days earlier...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

also participated in the financing, an unusual syndicate formed by investment funds of multiple large pharma companies...Supernus Pharmaceuticals Inc., of Rockville, Md., is raising $48 million in gross proceeds through a public offering

Shares of MEI Pharma Inc. (NASDAQ:MEIP) popped on Monday morning and climbed throughout the day after the company disclosed a $27.5 million private placement...The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...Novelos plans to use the proceeds to complete an in-house clinical-stage manufacturing facility for its small-molecule, broad-spectrum, cancer-targeted imaging agent I-124-CLR1404 (LIGHT

About a year earlier, Dutch firm AM-Pharma BV banked €29.2 million (then US$39.8 million) in a Series D round, apparently the largest venture capital financing in Dutch biotechnology thus far...The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase

Noting a trend for pharma companies to engage in more collaborations and acquisitions in order to supplement their pipelines with new technology, Lammers said he could envision such an outcome for Mirna...Given the interest of big pharma in microRNA companies, including Mirna, I'm convinced if we have strong human proof-of-concept data in the clinic, most likely pharma will be interested in stepping up to the plate," Lammers said

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.